BACKGROUND: To investigate the effect of stimulant medication [methylphenidate (MPH)] on growth patterns among survivors of childhood cancer (acute lymphoblastic leukemia or brain tumor). PROCEDURE: Using a case-matched comparison design, childhood cancer survivors participating in a 12-month open-label MPH trial (n = 51) were compared with childhood cancer survivors not taking MPH (n = 51). Measures of body mass index (BMI), height, and weight were obtained at hospital visits and corrected for gender and age using Centers for Disease Control normative data. RESULTS: Significant deceleration of BMI and weight, but not height, was observed during the 12-month MPH trial for those children taking MPH. CONCLUSIONS: Childhood cancer survivors taking MPH experience significant, though modest, deceleration of BMI and weight across the first year of MPH intervention. The absence of height deceleration, and the presence of only modest BMI and weight deceleration, suggests that MPH is reasonably well tolerated by childhood cancer survivors with respect to growth. Such findings are encouraging in light of increasing evidence that MPH mitigates some of the cognitive late-effects of cancer treatments. Nevertheless, on a case-by-case basis, clinicians should balance the intended benefits of MPH with potential growth effects in this vulnerable population.
BACKGROUND: To investigate the effect of stimulant medication [methylphenidate (MPH)] on growth patterns among survivors of childhood cancer (acute lymphoblastic leukemia or brain tumor). PROCEDURE: Using a case-matched comparison design, childhood cancer survivors participating in a 12-month open-label MPH trial (n = 51) were compared with childhood cancer survivors not taking MPH (n = 51). Measures of body mass index (BMI), height, and weight were obtained at hospital visits and corrected for gender and age using Centers for Disease Control normative data. RESULTS: Significant deceleration of BMI and weight, but not height, was observed during the 12-month MPH trial for those children taking MPH. CONCLUSIONS:Childhood cancer survivors taking MPH experience significant, though modest, deceleration of BMI and weight across the first year of MPH intervention. The absence of height deceleration, and the presence of only modest BMI and weight deceleration, suggests that MPH is reasonably well tolerated by childhood cancer survivors with respect to growth. Such findings are encouraging in light of increasing evidence that MPH mitigates some of the cognitive late-effects of cancer treatments. Nevertheless, on a case-by-case basis, clinicians should balance the intended benefits of MPH with potential growth effects in this vulnerable population.
Authors: Ronald T Brown; Robert W Amler; Wendy S Freeman; James M Perrin; Martin T Stein; Heidi M Feldman; Karen Pierce; Mark L Wolraich Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: Steven R Pliszka; Thomas L Matthews; Kenneth J Braslow; Melissa A Watson Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-05 Impact factor: 8.829
Authors: Carrie M Brownstein; Ann C Mertens; Pauline A Mitby; Marilyn Stovall; Jing Qin; Glenn Heller; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2004-09 Impact factor: 5.958
Authors: Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-06-14
Authors: James G Gurney; Kirsten K Ness; Marilyn Stovall; Suzanne Wolden; Judy A Punyko; Joseph P Neglia; Ann C Mertens; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 6.134
Authors: Heather M Conklin; Robert J Ogg; Jason M Ashford; Matthew A Scoggins; Ping Zou; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Sima Jeha; Lu Huang; Hui Zhang Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Heather M Conklin; Wilburn E Reddick; Jason Ashford; Susan Ogg; Scott C Howard; E Brannon Morris; Ronald Brown; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Sharon M Castellino; Janet A Tooze; Lynn Flowers; Debbie F Hill; Kevin P McMullen; Edward G Shaw; Susan K Parsons Journal: Pediatr Blood Cancer Date: 2012-01-11 Impact factor: 3.167
Authors: Raja B Khan; Maha Bano; Fang Wang; Pan Haitao; Anthony Christensen; Jessica Smith; Andrea Simmons; Zsila S Sadighi Journal: Pediatr Blood Cancer Date: 2020-10-13 Impact factor: 3.167